OCUL — Ocular Therapeutix, Inc.

Ocular Therapeutix Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: Ocular ended Q3 2025 with approximately $345 million in cash, not including $445 million from a recent equity financing, providing a cash runway into 2028.
• Financial Flexibility: The company emphasized its ability to fund ongoing clinical trials and prepare for commercialization.

2. Strategic Updates and Business Highlights

• AXPAXLI Development: The company is advancing its registrational studies for AXPAXLI (OTX-TKI) in wet AMD and diabetic retinopathy.
  • SOL-1 and SOL-R Trials: SOL-1 is on track for top-line data in Q1 2026, while SOL-R has reached its target randomization of 555 subjects.
  • HELIOS Program: A new initiative targeting diabetic retinopathy and diabetic macular edema (DME) is underway, designed to pursue a broad superiority label.
• Innovative Trial Design: The HELIOS trials will utilize an ordinal 2-step DRSS endpoint, which is expected to provide more clinically relevant data and increase statistical power.

3. Forward Guidance and Outlook

• Upcoming Data Releases: Top-line data for SOL-1 is expected in Q1 2026, and for SOL-R in the first half of 2027.
• Market Potential: The company aims to redefine the retina market by addressing the significant unmet needs in both wet AMD and diabetic retinal diseases, with a focus on increasing patient adherence and reducing treatment burden.

4. Bad News, Challenges, or Points of Concern

• Market Competition: The landscape for anti-VEGF therapies is becoming increasingly commoditized, with pricing pressures and the introduction of biosimilars.
• Regulatory Risks: While the company is optimistic about its labeling discussions, there is no guarantee of achieving the desired superiority label from the FDA.
• Patient Enrollment: Although initial enthusiasm for the HELIOS trials is high, there may be challenges in enrolling NPDR patients who are often reluctant to seek treatment.

5. Notable Q&A Insights

• Label Expectations: Dr. Dugel indicated that the initial label for wet AMD could include a superiority claim based on SOL-1, with flexibility in dosing intervals.
• Confidence in HELIOS Trials: The company expressed strong confidence in achieving a broad label for diabetic retinal disease, citing historical precedents for FDA approvals.
• Patient Retention: The retention rate in the SOL-1 trial exceeds 95%, indicating strong patient engagement, which is atypical for retina trials.
• Market Expansion: Ocular aims to capture a larger share of the anti-VEGF market by addressing the treatment gap for patients who currently do not receive therapy.

Overall, Ocular Therapeutix is positioned for significant advancements in its clinical programs, with a strong financial foundation and a clear strategic vision, despite facing competitive and regulatory challenges in the evolving retina market.